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Abstract
Genetic manipulation of human embryonic stem cells (hESCs) is instrumental for tracing lineage commitment and to
studying human development. Here we used hematopoietic-specific Wiskott-Aldrich syndrome gene (WAS)-promoter
driven lentiviral vectors (LVs) to achieve highly specific gene expression in hESCs-derived hematopoietic cells. We first
demonstrated that endogenous WAS gene was not expressed in undifferentiated hESCs but was evident in hemogenic
progenitors (CD45
2CD31
+CD34
+) and hematopoietic cells (CD45
+). Accordingly, WAS-promoter driven LVs were unable to
express the eGFP transgene in undifferentiated hESCs. eGFP
+ cells only appeared after embryoid body (EB) hematopoietic
differentiation. The phenotypic analysis of the eGFP
+ cells showed marking of different subpopulations at different days of
differentiation. At days 10–15, AWE LVs tag hemogenic and hematopoietic progenitors cells (CD45
2CD31
+CD34
dim and
CD45
+CD31
+CD34
dim) emerging from hESCs and at day 22 its expression became restricted to mature hematopoietic cells
(CD45
+CD33
+). Surprisingly, at day 10 of differentiation, the AWE vector also marked CD45
2CD31
low/2CD34
2 cells,
a population that disappeared at later stages of differentiation. We showed that the eGFP
+CD45
2CD31
+ population
generate 5 times more CD45
+ cells than the eGFP
2CD45
2CD31
+ indicating that the AWE vector was identifying
a subpopulation inside the CD45
2CD31
+ cells with higher hemogenic capacity. We also showed generation of CD45
+ cells
from the eGFP
+CD45
2CD31
low/2CD34
2 population but not from the eGFP
2CD45
2CD31
low/2CD34
2 cells. This is, to our
knowledge, the first report of a gene transfer vector which specifically labels hemogenic progenitors and hematopoietic
cells emerging from hESCs. We propose the use of WAS-promoter driven LVs as a novel tool to studying human
hematopoietic development.
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Introduction
Human embryonic stem cells (hESCs) are derived from the
inner cell mass of preimplantation embryos. They can differentiate
into cell types of the three germinal layers and under specific
culture conditions proliferate indefinitely [1,2,3]. hESCs represent
a unique tool for studying early human development, for cell
therapy and for developing in vitro models of human diseases
[4,5,6]. Genetic modification of hESCs is fundamental to explore
the mechanisms governing the balance between self-renewal and
lineage commitment through overexpression or silencing of
specific genes [7]. In addition, tracing lineage specification
demands the ability to express a reporter/marker gene (i.e. eGFP)
exclusively when lineage-specific cells emerge in vitro/in vivo.
However, unlike their murine counterparts, genetic modification
of hESCs is still very challenging due to the low efficiency of
existing delivery methods and to the strong silencing of the
transgenes [8].
Lentiviral vectors (LVs) are a powerful integrative system
[9,10] that can transduce most cell types including hESCs
[11,12]. They are one of the most promising gene delivery
methods for hESCs due to their high transduction efficiency and
stable expression. Latest generation self-inactivated lentiviral
vectors (SIN-LVs) express the transgene under internal promoters
[13,14] allowing the use of physiological or tissue-specific
promoters to obtain regulated transgene expression [15]. Using
this technology, several groups have developed cardiac-specific
lentiviral vectors able to specifically mark cardiomyocites derived
from hESCs [16,17,18]. However, no LVs capable of specifically
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39091marking blood cells differentiating from hESCs have been
reported so far.
In vitro differentiation of hESCs toward the hematopoietic
lineage provides a unique tool not only to study human
hematopoietic development and as a platform for drug screening
but also as a potential source for cell-gene therapy strategies
[19,20,21,22,23]. Using the embryoid body (EB) differentiation
model [24,25], hESC-derived hematopoietic cells emerge from
a subset of hemogenic progenitors expressing CD31, CD34, but
lacking CD45 (CD45
2CD31
+CD34
+ hemogenic progenitors)
[26]. Based on the CD34 expression levels, the CD45
2CD31
+
cells can be differentiated into hemato-endothelial progenitors
(CD45
2CD31
+CD34
bright)(also positive for VE-Cadherin and
KDR) and the hematopoietic-restricted progenitors
(CD45
2CD31
+CD34
dim) [4,27]. However, despite the fact that
hESC-derived hematopoietic cells show colony-forming unit
(CFU) capacity and a phenotype similar to somatic hematopoietic
cells, the in vivo generation of fully functional hESC-derived HSCs
capable of engrafting immunodeficient recipients still remains
a challenge [21,28,29,30] and will likely depend upon further
understanding of intrinsic molecular determinants.
Targeted expression of genes in hESCs-derived hematopoietic
cells will help to elucidate the mechanisms governing early
hematopoietic development and to design more efficient strategies
for the generation of hematopoietic stem cells (HSCs) from hESCs.
Our group has previously developed two different hematopoietic-
specific LVs, WE [31,32] and AWE [33] driving the expression of
eGFP through different promoter fragments of the Wiskott-
Aldrich Syndrome (WAS) gene (WAS). The WAS gene codifies
a hematopoietic specific protein involved in translating extracel-
lular signals to actin cytoskeleton polymerization and its expression
is driven by two different promoters, the proximal promoter [34]
and the alternative promoter located 3 kb upstream [35]. The WE
vector contains a 500 bp fragment of the proximal promoter and
the AWE vector harbors a longer version containing an additional
387 bp fragment of the alternative WAS promoter. In the present
study we demonstrated the usefulness of both the WE and AWE
LVs in achieving highly specific transgene expression in hESCs-
derived hemogenic progenitors and hematopoietic cells. eGFP
expression in WE- and AWE-transduced hESCs paralleled the
expression of endogenous WAS mRNA. Indeed, both LVs achieved
efficient integration in undifferentiated hESCs but they were
unable to express the transgene. However, eGFP expression was
efficiently driven by both vectors upon hematopoietic directed
differentiation. At day22 of hematopoietic differentiation most
eGFP
+ cells were mature hematopoietic cells (CD45
+CD33
+).
However, at days 10–15, the WAS-promoter driven LVs (WE and
AWE) tag cells with a phenotype corresponding to hematopoietic-
restricted hemogenic progenitors (CD45
2CD31
+CD34
dim) and
hematopoietic progenitors (CD45
+CD31
+CD34
dim). Interestingly,
at day 10 of differentiation, these vectors also marked
CD45
2CD31
low/2CD34
2 cells. In vitro assays of sorted popula-
tions showed hemogenic potential of eGFP
+CD45
2CD31
+ and
eGFP
+CD45
+CD31
+ as well as eGFP
+CD45
2CD31
low/2CD34
2
cells. Therefore, the AWE vectors were able to identify a new
population derived from hESCs with hemogenic potential. To our
knowledge, this is the first report of a gene transfer vector which
specifically tags hemogenic progenitors and hematopoietic cells
emerging from hESCs. This data opens up new avenues for
tracing human embryonic hematopoietic commitment allowing
not only the isolation, purification and characterization of early
hematopoietic progenitors but also the study of master hemato-
poietic genes.
Methods
Cell Lines and Culture Media
293T cells (CRL11268; American Type Culture Collection;
Rockville, MD) were grown in Dulbecco’s Modified Eagle
Medium (DMEM, Invitrogen, Edinburgh, Scotland) with Gluta-
MAX
TM and supplemented with 10% Fetal Bovine Serum (FBS)
(PAA Laboratories GmbH, Austria). Raji cells (CCL-86; ATCC)
were grown in RPMI-1640 media (Gibco) supplemented with 10%
FBS and glutamine 20 mM. Primary T cell lines (AlloT) were
generated and mantainned in our laboratory by weekly allo-
stimulation with mitomycin-C-treated Raji B-cells and cultured in
RPMI-1640 media supplemented with 10% FBS and glutamine
20 mM. HUVEC cells (TCS Cellworks, Buckingham, UK) were
grown in Medium 199 (Invitrogen) and supplemented with 20%
FBS, endothelial growth supplements (ECGS, Sigma Aldrich),
glutamine and heparin, AND-1 (Spanish Stem Cell Bank. www.
isciii.es) [36], SHEF-2 (UK Stem Cell Bank, Hertfordshire) and
H9 (Wicell Research Institute Inc. Madison, WI) hESC lines were
maintained undifferentiated in a feeder-free culture as previously
described [37] in Matrigel (BD Biosciences, Bedford, MA)-coated
p12 plates for lentiviral transduction and expanded in matrigel-
coated T25 flasks. Human ESCs were fed daily with human
mesenchymal stem cell-conditioned medium (MSC-CM) supple-
mented with 8 ng/ml bFGF (Miltenyi Biotech, Bergish Gladbach,
Germany), as described [22]. Media was changed daily and the
cells were split weekly by dissociation with 200 U/ml collagenase
IV (Invitrogen). Approval from the Spanish National Embryo
Ethical Committee was obtained to work with hESCs.
In vitro Hematopoietic Differentiation through Embryoid
Body (EB) Formation
Near confluent transduced hESCs (day 0) were treated with
collagenase IV for 1 min, and scraped off from the matrigel. The
hESCs were transferred to low-attachment plates (Corning Life
Sciences, Amsterdam, The Netherland) and incubated overnight
in media composed by KO-Dulbeccos modified Eagles medium
(Invitrogen) supplemented with 20% non-heat-inactivated FBS for
hESCs (Gibco), 1 mM glutamine, 0.1 mM non-essential amino
acids and 0.1 mM b-mercaptoethanol. The next day the EBs were
centrifuged and the media was changed for the same media
supplemented with BMP-4 (25 ng/ml), Flt-3L (300 ng/ml), SCF
(300 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml) and G-CSF
(50 ng/ml) [Chadwick, 2003 #1330], with media changes every
4 days. EBs were harvested for mRNA extraction at days 0, 1, 3, 5,
7, 11, 15 and 22, and dissociated using collagenase B (Roche
Diagnostic, Basel, Switzerland) for 2 hours at 37uC followed by
10 minutes incubation at 37uC with Cell Dissociation Buffer
(Gibco, Billings, MT) for FACS analysis and Colony Forming
Units (CFUs) assays.
FACS Analysis and Colony Forming Units (CFUs) Assays
The cells were resuspended in Iscove’s Modified Dulbecco’s
Media (IMDM) (for CFUs assays) or PBS1x +3%FBS+2m M
EDTA buffer (for FACS analysis). The cell suspension was filtered
through a 70-mm cell strainer (BD Biosciences, Bedford, MA) and
stained with fluorochrome conjugated monoclonal antibodies anti-
CD31-PE, anti-CD33-PE, anti-CD34-PE-Cy7 antibodies (all from
BD Biosciences) and anti-CD45-APC (Miltenyi Biotech, Bergish
Gladbach, Germany). Live cells identified by 7-AAD viability dye
exclusion were analyzed for surface-marker expression and eGFP
expression using a FACS Canto II flow cytometer equipped with
the FACS Diva analysis software (BD Biosciences). The popula-
tions analyzed were hemogenic progenitors
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2CD31
+CD34
+), hematopoietic progenitors
(CD45
+CD34
+), myeloid cells (CD45
+CD33
+) and total blood
cells (CD45
+). For pluripotency markers expression of the
transduced cells they were stained with the antibodies SEEA-3,
SSEA-4, TRA-1-60, TRA-1-81 and OCT3/4 (BD Biosciences).
For CFU assays, 20.000–35.000 cells were filtered through a 40-
mm cell strainer (BD Biosciences, Bedford, MA) and plated in
methylcellulose H4434 (Stem Cell Technologies, Vancouver,
Canada) supplemented with 30 U/ml of EPO. Cells were
incubated at 37uC, 5% CO2 humidified atmosphere. The colonies
were count based on morphological characteristics after 10 to
14 days [22] and analysed by FACS for CD14 (Miltenyi), CD45
and CD33 expression.
Analysis of the Hemogenic Potential of eGFP+ Cells
AWE-transduced cells were induced towards haematopoiesis as
described previously. At day 10 of differentiation, the EBs were
dissociated with colagenase B, stained for CD31 and CD45 and
washed with sterile PBS buffer supplemented with 2 mM EDTA,
3% FBS and penicilin/streptomycine. Live cells were identified by
7-AAD viability dye exclusion and four populations of cells were
sorted with a FACSAria flow citometer (BD Biosciences):
CD45
2CD31
+ GFP
2, CD45
2CD31
+ GFP
+, CD45
2CD31
2
GFP
2 and CD45
2CD31
2 GFP
+. The sorted cells (7–130610
3)
were cultivated in StemSpan media (StemCell Technologies
Vancouver, Canada) supplemented with Flt-3L (300 ng/ml),
SCF (300 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml) and G-CSF
(50 ng/ml), or in methylcellulose H4434. 7–15 days later, cells
were analyzed by FACS for the generation of hematopoietic cells
(CD45 expression) and colony formation.
Lentiviral Vectors (LVs)
The WE LV carries a 500-bp fragment of the WAS proximal
promoter driving the expression of eGFP [31,32,38] The AWE
LV was engineered by inserting a 387-bp fragment of the WAS
alternative promoter immediately upstream of the 500-bp WAS
proximal promoter in the WE vector.
35 Both vectors share the self
inactivated (SIN) lentiviral backbone described by Zuffery et. Al
[13]. The pLVTHM [39] (obtained from Addgene; plasmid
12247; http://www.addgene.org/12247) and CE [40] LVs,
driving the expression of eGFP through the EF1-a and CMV
promoters, respectively, were used as controls. All recombinant
DNA research follows the National Institutes of Health guidelines.
Vector Production and Transduction of hESCs
The human immunodeficiency virus (HIV) packaging
(pCMVDR8.91) and VSV-G (pMD2.G) plasmids (http://www.
addgene.org/Didier_Trono) are described elsewhere [13,41].
Vector production was performed as previously described [10].
Briefly, 293T cells were plated on amine-10-cm tissue culture
grade Petri dishes (Sarstedt, Newton, NC) the day before
transfection to ensure exponential growth and over 80%
confluence [32]. The vector (WE, AWE, CE or pLVTHM), the
packaging (pCMVDR8.91) and envelope plasmids (pMD2.G)
(proportion 3:2:1) were resuspended in 1.5 ml of Opti-MEM
(Gibco) mixed with 60 ml of Lipofectamine 2000 (Invitrogen). The
plasmid-lipofectamine mixture was added to pre-washed cells and
then incubated for 6–8 h. After 48 h, viral supernatants were
collected, filtered through 0.45 mm filter (Nalgene, Rochester, NY)
and concentrated by ultracentrifugation (Beckman Coulter) or by
ultrafiltration at 20006g and 4uC, using 100 Kd centrifugal filter
devices (Amicon Ultra-15, Millipore, Billerica, MA) as previously
described [42]. For transduction, human ESCs were dissociated
with collagenase type IV, scraped off of the matrigel and plated on
fresh matrigel-coated-p12-well plates. Immediately, fresh viral
particles were transferred onto them. The media was changed
after 5 hours. When the colonies reached confluence they were
split and expanded. The vector genome per cell of transduced-
hESCs was calculated from genomic DNA of 100,000 transduced
hESCs and 10-fold increasing amounts of plasmid DNA (from 10
2
to 10
7 copies) to determine the standard curve. The Q-PCR
(Mx3005P, Stratagene, La Jolla, CA) reaction consisted of 40
cycles at 94uC (15 sec), followed by 60uC (30 sec) and 72uC
(30 sec). eGFP primers used were: forward: 59- GTTCATCTG-
CACCACCGGCAAG-39 and reverse 59-
TTCGGGCATGGCGGACTTGA-39.
RNA Isolation, RT-PCR and Q-PCR Analysis
RNA from undifferentiated hESCs, hEBs, hemogenic precur-
sors and CD45+ blood cells was isolated using TRIzol (Invitrogen).
cDNA was generated with the SuperScript First-Strand Synthesis
System for RT-PCR (Invitrogen) and High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, California, USA).
RT-PCR cycles consisted in 109 25uC, 2 hours at 37uC, and 59 at
85uC. The cDNA was analyzed by quantitative real-time PCR
using Brilliant III Ultra-Fast SYBR Green QPCR Master Mix
(Agilent Technologies, La Jolla, CA) and the Mx3005P sequence
detector System (Stratagene). Q-PCR reaction consisted of 40
cycles at 94uC (15 sec), then 60uC (30 sec) and 72uC (30 sec).
Endogenous WAS expression was assessed using the following
primers: forward, 59-AGGCTGTGCGGCAGGAGAT-39 and
reverse 59-CAGTGGACCAGAACGACCCTTG-39), forward
GCTCTGGGAACAGGAGCTG and reverse
CTCGTCCTCGTCTGCAAAGT. The GAPDH gene was used
as control and relative expression was calculated using de DCT
method [43]. GAPDH primers were: forward, 59-GAAGGT-
GAAGGTCGGAGTC-39 and reverse, 59-GAAGATGGT-
GATGGGATTTC-39.
Neural Differentiation of hESCs
The protocol was slightly modified from that described by
Pankratz [44]. Briefly, hESC lines were grown in suspension as
hEBs in hESCs mdium as described previously for 4 days. The
hEBs were then cultured in neural medium composed by
DMEM/F12, nonessential amino acids, 2 mg/ml heparin, and
the neural cell supplement N2 (Gibco) for 3 additional days. Early
neural differentiation was evaluated at day 8 of culture by
dissociating and staining hEB single cells with the mouse anti-
human A2B5 (a neural embryonic antigen marker) (1:25 dilution;
Miltenyi Biotech) or the corresponding isotype control. APC-
conjugated goat anti-mouse antibody was used as secondary
antibody (Miltenyi Biotech).
Endothelial Differentiation of hESCs
To promote endothelial differentiation, the different hESCs
lines were seeded at density 10–30610
3 cells/cm
2 on plates coated
with 0.1% gelatin in EGM-2 complete media (Lonza Walkersville).
12 days later, the cells were detached with TryPLE (Invitrogen)
and washed with PBS buffer supplemented with 2 mM EDTA and
3% FBS. Endothelial differentiation was determined by FACS
analysis incubating with mouse anti-human VE-Cadherine-PE
(eBiosciences) using mouse IgG-PE isotype as control. Live cells
identified by 7-AAD viability dye exclusion were analyzed for
CD105, VE-cadherine and eGFP expression using a FACS Canto
II flow cytometer equipped with the FACS Diva analysis software
(BD Biosciences).
Tracing hESCs-Derived Hematopoietic Lineage
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All data are expressed as mean 6 SEM. Statistical comparisons
were performed (GraphPad Prism program) with nonparametric
test (Mann-Whitney test), two-tailed P value (95% confidence
interval). Statistical significance was defined as a P value ,0.05.
Results
Endogenous WAS Gene Expression Parallels
Hematopoietic Commitment from hESCs
Although the hematopoietic-specific expression of WAS gene is
well established [45,46,47], its expression pattern during early
hematopoietic development remains unknown. We therefore
studied WAS gene expression in hESCs during hematopoietic
differentiation (Figure 1). We first analyzed by RT-PCR the
relative endogenous WAS expression in non-hematopoietic cells
(293T and HUVEC) and hematopoietic (AlloT and Raji) cell
lines as well as in undifferentiated hESCs (AND-1 and SHEF-2)
and hESCs-derivedCFUs from AND-1 (Figure 1A). We con-
firmed that only hematopoietic cell lines (AlloT and Raji) or
hESCs-derived hematopoietic cells (AND-1 CFUs) expressed
WAS over background levels (Figure 1A). We could not detect
any significant expression of WAS in endothelial cells (HUVEC),
nor in undifferentiated hESCs (AND-1 and SHEF-2). However,
upon hematopoietic differentiation (see Figure S1 for details),
WAS expression appears early (day 3–5) and increased over time
(Figure 1B), paralleling hematopoietic commitment of hESCs. In
order to further characterize WAS expression during hematopoi-
etic commitment, we sorted CD45
2 CD31
2 non-hematopoietic
cells, CD45
2CD31
+ hemogenic progenitors and CD45
+CD31
+
hematopoietic cells at day 15 of differentiation and analyzed for
WAS expression (Figure 1C). In line with the expression kinetics
shown in Figure 1B, CD45
+ hematopoietic cells contained the
highest levels of WAS mRNA followed by CD31
+CD45
2
hemogenic progenitors. Together, this data indicates that WAS
expression parallels hematopoietic commitment from hESCs.
Expression of WAS-promoter Driven LVs is Restricted to
hESCs-derived Hematopoietic Lineage
We have previously described the development of two
hematopoietic-specific WAS-promoter-driven LVs: WE [31] an
AWE [33] (Figure 2A). The WE LV harbours a 500 bp fragment
from the WAS proximal promoter driving the expression of eGFP
and the AWE LV contains an additional 387 pb from the WAS
alternative promoter upstream of the proximal promoter. In order
to determine the ability of WE and AWE LVs to transduce hESCs,
we incubated the AND-1 cell line with the LV-containing
supernatants. Two other constitutive vectors, CE [40] and
pLVTHM [39], driving eGFP expression through the CMV and
EF1-a promoters respectively, were used as controls. All LVs
efficiently integrated into the hESCs (as determined by Q-PCR)
achieving 0.6–1.4 vector genome per cell (vg/c). However, only
the constitutive vectors CE and pLVTHM expressed the transgene
in the undifferentiated hESCs (Figure 2B). The transduction
protocol did not affect the pluripotency of the hESCs as
demonstrated by the expression of pluripotency markers and their
ability to form teratomas in NOD-SCID mice (data not shown).
We next studied whether the WE and AWE-transduced hESCs
expressed eGFP after hematopoietic differentiation. Transduced
hESCs were allowed to differentiate towards the hematopoietic
lineage through EB formation in the presence of hematopoietic
cytokines and 22 days later we measured the emergence of
hematopoietic and eGFP
+ cells. Upon hematopoietic differentia-
tion, eGFP expression was evident in both WAS-promoter driven
LVs. Importantly over 95% of the eGFP
+ cells were CD45
+ and
over 90% were CD45
+ CD33
+ myeloid cells (Figure 2C, right
plots). This indicates that eGFP
+ expression is labelling specifically
CD45
+ hematopoietic cells at day 22 of differentiation. However,
the constitutive pLVTHM vector expressed eGFP equally in
CD45
2 and CD45
+ cells (Figure 2C, bottom plots).
To compare the specificity of expression of WE versus AWE
vectors we analyzed the percentage of CD45
+ cells within the
eGFP
+ population at day 22 of differentiation (Figure 2D). Both
vectors performed very similar in marking hESCs-derived CD45
+
cells and we did not detected significance when comparing WE
and AWE vector (Figure 2D and Figure S2). However, the AWE
vector was slightly better than the WE vector when compared to
pLVTHM (P=0.0002 for AWE and P=0.0023 for WE). Based
on this data and on previous studies showing a more physiologic
expression of the AWE vector [33], we decided to focus in the
AWE vectors for subsequent experiments.
We further analysed whether differentiation of AWE-trans-
duced-hESCs to a non-hematopoietic lineage promoted transgene
expression. We used the AWE-transduced hESCs to differentiate
toward neuronal and endothelial lineages. The AWE vector was
unable to express eGFP when the hESC was differentiated toward
neither of the lineages (Figure 2E, top and middle plots). On the
other hand, when these hESCs were differentiated to the
hematopoietic lineage, eGFP started to be expressed in the
CD45
+ cells (Figure 2E, bottom plots and Figure 2C).
To further characterize AWE and WE expression pattern we
plated transduced-hESCs at day 15 of differentiation on methyl-
cellulose. CFU hematopoietic colonies were scored and analyzed
for CD45, CD33 and CD14 hematopoietic markers (Figure 3).
The results showed that the transduction protocol did not affect
CFU potential of the hESCs-derived progenitors (Figure 3A) and
about 40% of the colonies expressed eGFP regardless of the colony
subtype (Figure 3B, Figure S3 and data not shown). All eGFP
+
cells were CD45
+ (Figure 3C, right plots), about 82–86%
CD45
+CD33
+ and 7–9% CD45
+CD14
+. As expected, neither
the WE nor the AWE LVs expressed eGFP in the remaining
CD45
2 cells (Figure 3C).
The AWE Vectors Mark CD45
2CD31
low/2CD34
2,
CD45
2CD31
+ and CD45
+CD34
+ Cells Emerging from
hESCs at Early Days of Hematopoietic Differentiation
We further investigated the eGFP expression kinetics through
hematopoietic differentiation of AWE- and pLVTHM-transduced-
hESCs. Transduced hESCs were allowed to differentiate towards
thehematopoieticlineageandanalysedatdifferenttimepoints(days
10, 15 and 22). eGFP expression driven by the AWE LV was
manifested at day 10 and increased progressively at days 15 and 22
(Figure4A,blackplots)parallelingCD45expression(Figure4Aand
Figure S4). The phenotypic analysis of the eGFP
+ cells showed
specific marking of different subpopulations at different days of
differentiation. At day 10, around 33% of the eGFP
+ cells were
CD45
2CD31
+CD34
+, markers characteristic of hemogenic pro-
genitors (Figure 4A, Day 10, right plots, highlighted in red). 12%
wereCD45
+CD31
+hematopoieticcellsofwhich60%wereCD34
+,
markers that identify hematopoietic precursors (Figure 4A, Day 10,
right plots, highlighted in blue). The remaining 55% eGFP
+ cells
wereCD45
2CD31
low/2(Figure4A,Day10,rightplots,highlighted
in green). Note that the CD31 expression levels of eGFP
+ cells is
slightly higher than the observed in eGFP
2 cells (Figure 4A, right
plots, green population, versus left plots black population; day 10
and day 15). Further analysis of this population showed that they
werealsonegative forCD34(FigureS5).Wetherefore annotatethis
population as CD45
2CD31
low/2CD34
2. As differentiation con-
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+CD45
2 populations
disappeared(Figure4A,middle-rightplots,highlightedingreenand
red) and over 93% of the eGFP
+ cells became CD45
+CD31
+. The
phenotype of pLVTHM-transduced hESCs was identical in the
eGFP
+ and eGFP
2 regions (Figure 4B), indicating equal expression
of this vector in all populations.
Figure 1. WAS gene expression is restricted to hematopoietic cells and hemogenic progenitors. (A) Analysis of WAS gene expression in
different cell lines. mRNA was obtained from hematopoietic cell lines (AlloT and Raji), hESCs-derived myeloid CFUs (And-1 CFUs), undifferentiated
hESCs (AND-1 and SHEF-2), a human fibroblastic cell line (293T) and human endothelial cells (HUVEC) and analyzed by RT-PCR for WAS expression
(see M&M for details). (B) Time-course analysis of WAS gene expression during hematopoietic differentiation of AND-1 and H9 hESCs (see M&M and
Figure S1 for details). mRNA was extracted at different days during differentiation as indicated and WAS expression analyzed by RT-PCR. (C) Analysis
of WAS gene expression in hemogenic progenitors and hematopoietic cells. CD45
2CD31
+ (containing hemogenic progenitors) and CD45
+CD31
+
(containing hematopoietic cells) populations were sorter from AND-1 (left) and H9 (right) hESCs after 15 days of hematopoietic differentiation. WAS
mRNA relative levels were determined in sorted cells by RT-PCR. DCt value for WAS expression was obtained using GAPDH as reference gene in all
experiments. CFUs: Colony Forming Units.
doi:10.1371/journal.pone.0039091.g001
Tracing hESCs-Derived Hematopoietic Lineage
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39091Interestingly, the AWE LV marked only CD31
+ cells expressing
moderate-low levels of CD34 (CD34
dim). This is more evident in
the CD45
2CD31
+ population at day 10 of differentiation where
the CD34
bright population in the eGFP
- region completely
disappeared in the eGFP
+ region (Figure 4A, highlighted in red,
Figure 4C and Figure S5). The same was observed for the WE LV
(Figure S6). To confirm these data we used two different hESCs
lines (H9 and AND-1) and compared the fold enrichment in
CD34
dim and CD34
bright subpopulations from hemogenic
(CD45
2CD31
+) and hematopoietic progenitors (CD45
+CD31
+)
in the eGFP
+ versus eGFP
2 populations (Figure 4C). We also
included the CD45
+CD33
+CD34
2 cells in this study to compare
Figure 2. Specific expression of WAS-promoter driven LVs in hESCs-derived hematopoietic cells. (A) Representation of the SIN LVs used
to transduce hESCs. WE vector [31] contains a 500-bp fragment of the human WAS proximal promoter driving the expression of the reporter gene
eGFP. The AWE vector [33] contains an aditional 387-bp fragment of the WAS alternative promoter. The CE and pLVTHM are control lentiviral vectors
expressing constitutively eGFP through the CMV and the EF1a promoters, respectively. (B) Constitutive LVs (CE and pLVTHM) express eGFP in hESC
undifferentiated cells (AND-1) while the hematopoietic-specific AWE and WE LVs are silent. AND-1 cells were transduced with the LVs in order to
obtain 0.5–3 vg/c (see materials and methods). (C) Hematopoietic differentiation induces eGFP expression in AWE and WE-transduced hESCs. AWE-,
WE- and pLVTHM- transduced H9 cells were prompt to differentiate and 22 days later analyzed for eGFP expression (Middle plots). eGFP
+ (right) and
eGFP
2 (left) populations were analyzed for expression of mature hematopoietic markers CD45 and CD33. Note that WE and AWE-transduced cells
(top and middle plots) mark specifically CD45
+CD33
+ cells while pLVTHM (bottom plots) express eGFP equally in hematopoietic and non-
hematopoietic cells. (D) Graph showing the percentage of CD45
+ cells within the eGFP
+ population from AWE-, WE- and pLVTHM-transduced hESCs
at day 22. AWE and WE- transduced cells did not show statistics differences. pLVTHM-transduced hESCs were used as controls. Data are average of at
least three independent experiments +/2 SEM *** P=0.0002; ** P=0.0023 (E) Neuronal and endothelial differentiation of AWE-transduced hESCs
does not induce eGFP expression. AWE-transduced H9 cells (AWE) were differentiated into neural progenitors (Top plots) and endothelium (middle
plots) and analyzed for eGFP, A2B5 (an early neuroectodermal marker) and VE-Cadherine (an endothelial marker) expression. The AWE-transduced H9
cells were also used for EB-mediated hematopoietic differentiation and analyzed after 22 days for eGFP and CD45 (Right plot). Untransduced (NT) H9
were used as a negative control for eGFP expression.
doi:10.1371/journal.pone.0039091.g002
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cells. The data corroborated that eGFP
+ cells specifically tag
CD34
dim cells in both CD45
2CD31
+ and CD45
+CD31
+ cells.
The AWE Vectors Mark Early Hemogenic Progenitors
We have showed that eGFP
+ cells emerging from differentiated
AWE-transduced hESCs at day 10 expressed different markers
identifying hemogenic (CD45
2CD31
+CD34
dim) and hematopoi-
etic progenitors (CD45
+CD31
+CD34
dim) as well as a singular
CD45
2CD31
dim/2CD34
2 population. Our next aim was there-
fore to determine whether these eGFP
+ populations had real
hemogenic potential. In first place we sorted eGFP
+ as well as
CD34
+ cells from hematopoietic differentiated hESCs (day 10) and
analyzed its CFU potential in methylcellulose (Figure 5A). We
showed that the eGFP
+ cells produced a similar number of
hematopoietic colonies than CD34
+ cells confirming the ability of
the AWE vector to tag hematopoietic precursors.
We next investigated whether the eGFP
+ cells identify a distinct
population inside the CD45
2CD31
+ since they differ in the
expression levels of CD34. We separated CD45
2CD31
+eGFP
2
(CD34
bright and CD34
dim) and CD45
2CD31
+eGFP
+ (CD34
dim)
from day 10 hESCs and incubated them on StemSpan media
Figure 3. WAS-promoter driven LVs efficiently express eGFP in hESC-derived myeloid colonies. AWE and WE-transduced hESCs were
plated in EB hematopoietic differentiation media for 15 days and then seeded in methylcellulose H4434 (Stem Cell Technologies, Vancouver, Canada).
(A) Graph showing CFU efficiency obtained from AWE and WE-transduced hESCs compared to untransduced hESCs (NT). Data are shown as average
from three independent experiments +/2 SEM. (B) Phase contrast (Top panels) and fluorescence (bottom panels) microphotographs from AWE-
transduced hESCs derived CFUs. (C) Phenotypic analysis of cells derived from AWE and WE-transduced hESCs. eGFP
+ (right plots) and eGFP
2 (left
plots) populations were analyzed for expression of mature hematopoietic markers CD45, CD33 and CD14.
doi:10.1371/journal.pone.0039091.g003
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39091supplemented with cytokines (Figure 5B). Interestingly the data
showed that the eGFP
+CD45
2CD31
+ population generate 5 times
more CD45
+ cells than the eGFP
2CD45
2CD31
+ cells (Figures 5B
and 5D). This indicates that the AWE vector can mark a sub-
population inside the CD45
2CD31
+ cells with higher hemogenic
potential, probably due to the enrichment in hematopoietic-
restricted (CD34
dim) progenitors.
The expression of eGFP in the CD45
2CD31
low/2CD34
2
hESCs-derived cells prompt us to investigate whether these cells
represented a hemogenic precursor. We sorted
CD45
2CD31
2eGFP
2 and CD45
2CD31
2eGFP
+ (see
Figure 5C). Post-sorting analysis of both populations showed
a slightly higher expression of CD31 on eGFP
+ cells compared to
eGFP
2 cells, indicating that the eGFP
+ express low but significant
amounts of CD31 (Figure S7). Both populations (CD45
2CD31
low/
2eGFP
+ and CD45
2CD31
2eGFP
2) were incubated in StemSpan
media supplemented by hematopoietic factors (See M&M).
Interestingly, only the CD45
2CD31
low/2eGFP
+ sorted cells
render CD45 positive cells that were also eGFP
+ (Figure 5C,
right-black plots) indicating that the AWE vector is able to identify
a subpopulation, CD45
2CD31
low/2CD34
2 with hemogenic
potential.
Discussion
Tracing lineage specification demands the ability to efficiently
express a reporter/marker gene (i.e. eGFP) exclusively when
lineage-specific cells emerge in vitro/in vivo. In the present
manuscript we have studied the feasibility of specifically marking
hESC-derived hematopoietic cells with WAS-promoter driven
lentiviral vectors (WE and AWE). We were also interested in
determining the ability of both vectors to mimic the expression
pattern of the endogenous WAS gene during the different stages of
human hematopoietic differentiation. We have shown that hESCs
do not express the WAS gene until they are committed to
hematopoietic lineage. WAS expression started to be detected in
hemogenic progenitor cells (CD45
2CD31
+) and to a higher extent
in the CD45
+ hematopoietic cells. This is the first report showing
that the WAS gene is expressed in human hemogenic progenitors.
Several groups have developed cardiac-specific LVs able to
specifically mark cardiomyogenic cells derived from hESCs
[16,17,18]. The establishment of transgenic hESCs lines that
specifically mark human differentiated cardiomyocytes has allowed
the purification (up to 96% pure) and analysis of hESC-derived
cardiomyocytes [48]. The use of these transgenic cell lines has also
allowed the in vivo study of hESCs-derived cardiomyogenic
differentiation from hESCs to multiple cardiomyocytes subtypes
and the identification of early myocardial precursors derived from
hESCs (hMPs) using an alpha-myosin heavy chain (alphaMHC)-
GFP reporter line [18]. Since we found that WAS gene expression
was turned on after hematopoietic differentiation, we hypothesized
that a gene delivery vector expressing eGFP through the WAS
gene promoter could be used to trace hematopoietic cells derived
from hESCs. Our experiments showed that eGFP expression in
AWE and WE-transduced hESCs followed a similar expression
pattern than the endogenous WAS gene during hematopoietic
differentiation. Although both LVs were very efficient integrating
their cargo into the hESCs they failed to express the transgene in
undifferentiated hESCs and required hematopoietic differentiation
to express eGFP. This data indicates that undifferentiated hESC
do not contain the required transcription factors to activate the
WAS promoter, as suggested also by the absence of endogenous
WAS mRNA in these cells. Although the expression pattern of the
WE and AWE vectors were very similar, we detected a slightly
higher (although not significant) specificity of the AWE. In
addition, in previous studies [33] we showed a more physiological
behaviour of the AWE vectors. We therefore selected the AWE
vector for in-detail analysis of the WAS-promoter driven LVs as
a tool to identify hemogenic progenitors and hematopoietic cells
emerging from hESCs.
We first showed that hESCs were not affected in their
potential to differentiate to the different germ layers after LVs
transduction andthe hematopoietic derivatives from transduced-
hESCs were phenotypically indistinguishable to control hESCs.
A detailed analysis of the eGFP expressing cells emerging during
hematopoietic differentiation of the AWE-transduced hESCs
showed that this vector were able to mark different cell types. At
early stages of hematopoietic differentiation, the AWE vector
mark cells previously identified as hemogenic
(CD45
2CD31
+CD34
+) and hematopoietic progenitors
(CD45
+CD34
+) as well as CD45
2CD31
low/2CD34
2 cells. We
demonstrated that WAS-promoter driven LVs identify hemato-
poieitic progenitors emerging from hESCs with similar efficiency
than selection with anti-CD34 antibodies. Indeed, day10-eGFP
expressing cells had similar CFU potential in methylcellulose
than CD34
+ cells isolated from the same culture. These results
opened the possibility of isolate progenitors using only eGFP
expression or combining eGFP and other known markers for
hemogenic and hematopoietic progenitors.
Taken advantage of this possibility we decided to analyze the
hemogenic potential of the CD45
2CD31
+ and CD45
2CD31
2
cells identified by the AWE vectors. An interesting finding in this
work is that the AWE mark a subpopulation inside the
CD45
2CD31
+ cells expressing low-moderate levels of CD34
(CD34
dim), a characteristic defined for some authors as hemato-
poietic-restricted progenitors, in contrast to the CD34
bright found
in hemato-endothelial progenitors [4,27]. Our experiments
showed that the eGFP
+CD45
2CD31
+ cells were up to 6 times
better generating CD45
+ cells than the eGFP
2CD45
2CD31
+ cells
when incubated in a medium that allows hematopoietic differen-
tiation. These data clearly demonstrate the hemogenic potential of
the eGFP
+CD45
2CD31
+ cells and favour the hypothesis that they
could represent a hematopoietic-restricted progenitor. Conse-
quently, the eGFP expression of AWE-transduced hESCs at early-
Figure 4. The AWE vectors identify different sub-populations at different times of hematopoietic differentiations. (A) AWE-
transduced H9 cells were incubated in hematopoietic differentiation media and analyzed for CD45, CD31 and CD34 expression at days 10, 15 and 22.
eGFP
+ (right) and eGFP
2 (left) populations were first analyzed for expression of CD45 and CD31. hESCs CD31
+CD45
+ and CD31
+CD45
2 were further
analyzed for expression of CD34 (top and bottom plots respectively). (B) A similar experiment as in A) was performed using pLVTHM -transduced H9
cells. Note that using the pLVTHM constitutive vectors there are no differences in eGFP expression from day 10 to day 22. (C) AWE- marked cells are
enriched in CD34
dim hemogenic progenitors and hematopoietic cells. Graph representing fold enrichment of eGFP
+ versus eGFP
2 population in
hemogenic progenitors (CD45
2CD31
+), hematopoietic progenitors (CD45
+CD34
+) and myeloid cells (CD45
+CD33
+). CD34
dim and CD34
bright
progenitor cells were analyzed independently. Data were obtained by dividing the percentages of the different cell types in the eGFP
+ fraction of the
AWE-transduced hESCs (from Figure 4A, right plots) with the values obtained in the eGFP
2 population (Figure 4A, left plots) and plotted as fold
enrichment. Data represent average of at least five separate experiments (+/2 SEM) using H9 and AND-1cells at medium stage of hematopoietic
development (day 10 for H9 and day 15 for AND-1). ** P=0.008; * P=0.032.
doi:10.1371/journal.pone.0039091.g004
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39091Figure 5. The AWE vector tag hemogenic and hematopoietic progenitors. (A) CFU potential of eGFP+ cells. AWE- transduced H9 cells were
incubated in EB hematopoietic differentiation media. 10–12 days later, eGFP
+ and CD34
+ cells were sorted and seeded in methylcellulose H4434
(Stem Cell Technologies, Vancouver, Canada). Left graph shows CFU efficiency obtained from eGFP+ sorted cells compared to CD34
+. Data are shown
as average from three independent experiments +/2 SEM. Right graphs shows relative frequency of the different types of colonies (G= granulocytes;
GM= Granulocytes/macrophages; M=Macrophages) obtained from eGFP
+ (left) and CD34
+ (right) sorted cells. (B) Hemogenic potential of
CD45
2CD31
+ cells expressing eGFP. AWE- transduced H9 cells were incubated in EB hematopoietic differentiation media. 10–12 days later the cells
were analyzed for eGFP (top left plot) as well as CD45 and CD31 expression (top right plot). CD31
+eGFP
2 (left panels) and CD31
+eGFP
+ (right panels)
were sorted and induced in StemSpan with Flt-3L, SCF, IL-3, IL-6 and G-CSF(see M&M). Expression of CD45 and eGFP was analyzed 10 days later
(bottom-black plots). (C) Hemogenic potential of CD45
2CD31
2 cells expressing eGFP. AWE- transduced H9 cells were incubated in EB hematopoietic
differentiation media. 10–12 days later differentiated cells were analyzed as above. CD31
2eGFP
2 (left panels) and CD31
2eGFP
+ (right panels) were
sorted and induced to differentiate toward haematopoiesis as above. Note that the CD45
2CD31
2eGFP
+ cells (but not the CD45
2CD31
2eGFP
2)
generate CD45
+ cells. (D) Hemogenic efficiency of AWE-labelled CD45
2 populations. Graph showing the fold enrichment in hemogenic progenitors
of the eGFP
+ versus the eGFP
2 cells on CD31
+ and CD31
2 cells. Data were obtained by dividing the percentages of CD45
+ cells derived from the
eGFP
+CD31
+ sorted cells with the values obtained with the eGFP
2CD31
+ sorted cells (left column) or eGFP
+CD31
2 sorted cells with eGFP
2CD31
2
sorted cells (right column).
doi:10.1371/journal.pone.0039091.g005
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interesting marker to study the CD34
dim and CD34
bright
populations. For example, by sorting eGFP
2CD34
bright and
eGFP
2CD34
2 cells at day 9–10 would be possible to trace the
origin of the eGFP
+CD45
2CD31
+CD34
dim and
eGFP
+CD45
+CD31
+CD34
dim cells.
As mentioned before, half of the eGFP
+ cells at day 10 were
negative for the CD45, CD31 and CD34 markers. Since they
expressed eGFP through the AWE LVs, they could represent pre-
hematopoietic mesodermal precursors able to differentiate into
hematopoietic cells. However, another possible explanation would
be that the AWE vector is expressing eGFP in non-hematopoietic
cells. There were several facts favouring the hypothesis that these
eGFP
+CD45
2CD31
low/2CD34
2 cells could represent a new
subpopulation of hemogenic progenitors: a) The AWE
eGFP
+CD45
2CD31
low/2CD34
2 population is transient and only
present at early-intermediate stages of the hematopoietic de-
velopment indicating they could be pre-hemato mesodermal
precursors. b) The emergence of CD45
+ cells coincide with the
disappearance of the AWE eGFP
+CD45
2CD31
low/2CD34
2 cells.
c) The eGFP
+CD45
2CD31
low/2CD34
2 population obtained
from the pLVTHM-transduced hESCs do not disappear at later
stages of differentiation. In order to corroborate this hypothesis we
sorted eGFP
+CD45
2CD31
low/2 and eGFP
2CD45
2CD31
2 cells
and showed that only the eGFP
+ cells have the potential to
generate CD45
+ cells. Therefore the AWE eGFP
+CD45
2C-
D31
low/2CD34
2 population represent a previously unidentified
hemogenic progenitors. It is interesting to mention a recently
published manuscript by the group of Dr Berardi [49] that
identified a new adult human circulating
CD45
2Lin
2CD34
2CD133
2 cells that can differentiate to hema-
topoietic and endothelial cells. These cells are somehow similar to
our eGFP
+CD45
2CD31
low/2CD34
2 population. It would be
therefore interesting to further characterize the eGFP
+CD45
2C-
D31
low/2CD34
2 population as a possible cellular model mimick-
ing this rare population found in adult blood.
In summary, we have shown the usefulness of WAS-promoter
driven LVs (AWE and WE) to specifically express transgenes in
hESCs-derived hematopoietic cells. We have demonstrated that
the AWE and WE LVs specifically expressed eGFP in hemogenic
and hematopoietic progenitors at day 10–15 of differentiation.
Interestingly, these LVs were able to discriminate between the
hematopoietic-restricted hemogenic progenitors
(eGFP
+CD45
2CD31
+CD34
dim) and the hemato-endothelial he-
mogenic progenitors (eGFP
2CD45
2CD31
+CD34
bright). There-
fore, the characteristic expression pattern of the AWE vector
opens up new opportunities to study hematopoietic development.
The AWE vector could be used as a tool for isolation/purification
of early hematopoietic progenitors, for high throughput screening
to identify molecules involved in hematopoiesis and/or for the
specific expression of transgenes in hESC-derived hematopoietic
cells. In addition our data point to the potential of the WAS gene as
a new marker for hemogenic and hematopoietic progenitors.
Supporting Information
Figure S1 Schematic diagram showing the procedure
for hematopoietic differentiation of hESCs. hESC are
incubated in non-adherent plates in EBs medium (see
M&M for details). Once the EBs are formed, the media is
replaced for EB medium supplemented with hematopoietic
cytokines and incubated for 22days. Total RNA was obtained at
different the days (0, 1, 3, 5, 7, 11, 15 and 22) during
hematopoietic differentiation for RT-PCR. For FACS analysis,
EBs were dissociated and analyzed at days 10, 15 and 22. For
CFU formation, EBs were dissociated at day 15 and incubated in
methylcellulose.
(TIF)
Figure S2 Lentiviral transduction does not affect hema-
topoietic differentiation potential of hESCs. Untransduced
nESCs (NT) and AWE- and WE-transduced H9 cells were
induced towards hematopoiesis by EBs formation. At day 15 of
differentiation (top), the EBs were dissociated and analyzed for
CD31 and CD45 expression to determine the percentage of
CD31+CD45- hemogenic cells (top graph). At day 22 of
differentiation (bottom) we analyzed the percentage of cells
expressing CD45. Data represent individual experiments.
(TIF)
Figure S3 WAS-promoter driven LVs efficiently express
eGFP in hESC-derived myeloid colonies. Transmission (left
panels) and fluorescence (right panels) microphotographs from
untransduced (NT), pLVTHM-, AWE- and WE-transduced
hESCs. The different hESCs were incubated in EB hematopoietic
differentiation media for 15 days and then incubated in
methylcellulose H4434 (Stem Cell Technologies, Vancouver,
Canada). Pictures were taken after 10 days in methylcellulose.
Note the expression of eGFP in both, hematopoietic (colonies,
round-shape cells) as well as in non-hematopietic cells (big,
adherent cells) in hESCs transduced with the pLVTHM vector.
However, the WAS-promoter driven LV, AWE and WE, only
express eGFP in myeloid colonies and not in background cells.
(TIF)
Figure S4 Expression pattern of WAS-promoter driven
lentiviral vectors parallel CD45 expression during
hESCs hematopoietic development. Graphs showing the
percentage of eGFP
+ (A) and CD45
+ (B) cells in AWE and WE-
transduced H9 cells at different days of hematopoietic differenti-
ation. Untransduced cells (NT) were used as negative controls.
Data are average +/2SEM from 3 independent experiments
(TIF)
Figure S5 Phenotypic analysis of the CD45
2eGFP
+cells
in AWE-transduced H9 and AND-1 hESCs at days 10–15
of EB differentiation. pLVTHM- and AWE-transduced H9
and AWE-transduced AND-1 cells were incubated in hematopoi-
etic differentiation media and analyzed for CD45 and eGFP
expression (middle plots) after 10 (H9) or 15 (AND-1) days.
CD45
2eGFP
2 (left plots) and CD45
2eGFP
+ (right plots) were
further analyzed for expression of CD34 and CD31. Compared to
the eGFP
2 population (left plots) or eGFP
+ cells from pLVTHM-
transduced hESCs (bottom-right plots), eGFP+ cells derived from
AWE-transduced hESCs (top and middle right plots) lost most of
the CD31
+CD34
bright cells and were enriched in CD31
+CD34
dim
cells.
(TIF)
Figure S6 Phenotypic analysis of eGFP
+ cells in WE-
transduced H9 cells at days 10, 15 and 22 of differen-
tiation. WE-transduced H9 cells were incubated in hematopoi-
etic differentiation media and analyzed for CD45, CD31 and
CD34 expression at days 10, 15 and 22. eGFP
+ (right) and eGFP
2
(left) populations were first analyzed for expression of CD45 and
CD31. CD31
+CD45
+ and CD31
+CD45
2 were further analyzed
for expression of CD34 (top and bottom plots respectively).
(TIF)
Figure S7 Phenotypoic analysis of sorted populations.
The AWE-transduced H9 cells were induced towards hematopoi-
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39091esis by EBs formation (see M&M). At day 10 of differentiation, the
EBs were dissociated and the different populations sorted. A) Cells
were separated based on the expression of eGFP (left plot, arrows)
or CD34 (right plot, arrows). eGFP- and eGFP+ sorted cells were
analyzed for eGFP expression (left histograms). CD34- and
CD34+ cells were analyzed for CD34 expression (right histo-
grams). B) Top plots show the regions used for the sorting of
GFP+CD31- and GFP-CD31-. After the separation, the different
populations were analyzed for expression of eGFP and CD31
(Bottom histograms). Note the enhanced expression of CD31 in
eGFP+ cells compared to the eGFP- cells (bottom histograms)
(TIF)
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